In the original article, we neglected to include the funder NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick’s Foundation.
The revised “Funding” should read:
This work was supported by ARRA grant from the National Institutes of Health, by grant from the Department of Defense (AY) # W81XWH-12-1-0427, by grant from the NIH (AY) #5R01CA164132, the Lou Bridgeman Memorial Fund, the Alex’s Lemonade Stand Foundation (AY), NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick’s Foundation and COG SDC grant U10CA180899.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
The original article has been updated.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Summary
Keywords
neuroblastoma, immunotherapy, anti-GD2 chimeric antibody, cytokines, safety, cytokine biomarkers
Citation
Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM and Yu AL (2018) Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931. Front. Immunol. 9:1641. doi: 10.3389/fimmu.2018.01641
Received
02 July 2018
Accepted
03 July 2018
Published
16 July 2018
Volume
9 - 2018
Edited and reviewed by
Frontiers in Immunology Editorial Office, Frontiers Media SA, Switzerland
Updates
Copyright
© 2018 Ozkaynak, Gilman, London, Naranjo, Diccianni, Tenney, Smith, Messer, Seeger, Reynolds, Smith, Shulkin, Parisi, Maris, Park, Sondel and Yu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: M. Fevzi Ozkaynak, mehmet_ozkaynak@nymc.edu; Alice L. Yu, a1yu@ucsd.edu
Specialty section: This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.